|
|
|
|
|
Detail |
| hsa-miR-93 |
|
Unspecified |
MYCN regulates oncogenic MicroRNAs in neuroblastoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Unspecified |
Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. |
2006 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Causal |
E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. |
2008 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Unspecified |
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. |
2007 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Causal |
Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. |
2007 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Unspecified |
Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. |
2008 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Causal |
miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. |
2009 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Unspecified |
Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer |
2009 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Unspecified |
MicroRNA expression profiles in serous ovarian carcinoma. |
2008 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Unspecified |
Heterogeneous dysregulation of microRNAs across the autism spectrum. |
2008 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Causal |
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. |
2008 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Causal |
Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. |
2008 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Causal |
Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. |
2009 |
|
|
|
|
|
|
| hsa-miR-93 |
|
Causal |
Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. |
2009 |
|
|
|
|
|
|